Making Order from Chaos
For the first time in my three decades in medicine, the federal government is no longer to be trusted with respect to medical advice. This creates a confusing mess for patients looking to make good...
View ArticleSotatercept: ZENITH and HYPERION Trials
Sotatercept, the newest drug approved to treat pulmonary arterial hypertension (PAH) has been on the market Since May of 2024. In the phase 2 PULSAR trial and phase 3 STELLAR trial, sotatercept...
View ArticleClik here to view.
In Memoriam: Greg Ahearn, MD
The pulmonary hypertension community lost a Giant today. I met Dr. Ahearn in the end of 2003. He was leaving Duke where he had trained and was working as an attending physician on the pulmonary...
View ArticleClik here to view.
Sotatercept (Winrevair) Approved!
On March 26, 2024 the FDA approved sotatercept (brand name of Winrevair), the first new class of medication approved in over a decade. This medication acts by inhibiting signaling in the Activin...
View ArticleDisappointing News for Rodatristat Ethyl
In July 2023, Enzyvant, now Sumitomo Pharma America, a subsidiary of Sumitomo Pharma, announced an update on their Phase 2 ELEVATE 2 study of Rodatristat Ethyl for PAH. The Phase 2b study failed to...
View ArticleSotatercept Coming Soon
A new drug is poised to enter the PAH market and offers great promise for patients. This new drug works in a completely different way from all the currently approved medications. Sotatercept is an...
View ArticleClik here to view.
Why Abortion Matters to PAH Patients
Across America a woman’s right to terminate an unwanted pregnancy is under threat. Without diving into politics or religion I want to impress on the PAH community why this may spell disaster for our...
View ArticleAerovate and Inhaled Imatinib
Imatinib is a tyrosine kinase inhibitor that has been on the market for more than 20 years to treat a type of leukemia. It acts by turning off tyrosine kinases. You can think of tyrosine kinases as...
View ArticleClik here to view.
Sotatercept for Pulmonary Arterial Hypertension
For the past 30 years, all our pulmonary arterial hypertension medications were described as vasodilators: First prostanoids (epoprostenol), then endothelin receptor antagonists (bosentan,...
View ArticleClik here to view.
Back in Action
Please forgive the hiatus in posting new content. When I am not caring for pulmonary hypertension and pulmonary fibrosis patients I am also an intensive care unit doctor and have been inundated caring...
View ArticleClik here to view.
Pulmonary Hypertension and Interstitial Lung Disease
Pulmonary hypertension (elevated pressure within the blood vessels of the lungs) is organized into five groups: Group 1: Pulmonary arterial hypertension (PAH) Group 2: Pulmonary venous hypertension...
View ArticleClik here to view.
Lung Transplantation with PAH
For Pulmonary Arterial Hypertension (PAH) patients who remain very short of breath despite maximal medical therapy, lung transplantation may be an option. Maximal medical therapy usually means...
View ArticleClik here to view.
Porto-Pulmonary Syndrome
An important cause of PAH is liver disease. Up to 5% of patients with cirrhosis (scarring in the liver) or portal hypertension (high pressure in the blood vessels of the liver) can develop PAH. All...
View ArticleClik here to view.
Major Drug Developments in PAH July 2020
In a surprising development, Complexa abruptly terminated their phase 2 study in PAH. They seem to have taken a page from Reata’s playbook. The news blindsided the PAH community and is a reminder...
View ArticleClik here to view.
FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH,...
During the past few months, we have not had quite as much time as usual to address our readers questions. Apologies for that. When I am not caring for pulmonary hypertension patients, I wear a...
View ArticleClik here to view.
Acceleron Announces a Positive Trial
PULSAR Phase 2 Study Results This was a very exciting week in the world of pulmonary arterial hypertension. Acceleron announced the results of their PULSAR phase 2 study. This study used...
View ArticleClik here to view.
Serotonin and Pulmonary Arterial Hypertension
Serotonin is an important molecule in our bodies. It works in our brain to regulate mood, appetite, sleep, memory and probably many other aspects of our behavior. In the 1960’s and early 1970’s a...
View ArticleClik here to view.
Getting the Most from the Holiday Season with PAH
The holidays are a time to spend with family and friends and reflect on the past year and think about the upcoming year. This sounds wonderful and low stress. Nothing could be further from the...
View ArticleClik here to view.
Uptravi (Selexipag) for PAH
Uptravi was approved in 2016 to treat Pulmonary Arterial Hypertension, PAH. We now have more than four years of experience with this medication. There are three broad pathways that PAH medications...
View ArticleClik here to view.
Exciting New Clinical Trials in PAH
The wheels of progress continue to move forward in PAH research. Two companies in particular are preparing to launch very exciting clinical trials. Gossamer Bio Inhaled Drug Study Gossamer Bio, a...
View Article
![ONEW – KAKERA -Unmei no Piece- – EP [iTunes Plus M4A]](http://is1-ssl.mzstatic.com/image/thumb/Music221/v4/d0/fb/86/d0fb86a5-ba60-4bea-41fb-7f54c125f518/VEATP-45908.jpg/296x296bb.webp)
